ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
Objective: Characterize the levodopa pharmacokinetic profile derived from continuous subcutaneous (SC) administration of ND0612. Background: Continuous levodopa/carbidopa (LD/CD) infusion is considered the optimal delivery route…Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions
Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Objective: To identify genetic risk factors for developing levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD). Background: LID are common complications in PD, but…Identification of the optimal carbidopa concentration in subcutaneously administered ND0612
Objective: To identify the concentration of subcutaneous (SC) carbidopa (CD) that provides optimal bioavailability of a concomitant fixed concentration of levodopa (LD) when administered via…The influences of STN-DBS and levodopa on cardiovascular autonomic function in patients with Parkinson’s disease: Evaluated by trigonometric regressive spectral analysis
Objective: To explore the effects of STN-DBS and levodopa on cardiovascular autonomic function in PD. Background: Cardiovascular autonomic dysfunction has been shown in patients with…Changes in serum amino acid levels with progression of Parkinson’s disease
Objective: The purpose of this study was to analyze changes in serum amino acid profile with progression of Parkinson's disease (PD). Background: PD is a…The relationship between impulse control disorders and dyskinesia in Parkinson´s disease: The ALTHEA study
Objective: To report (1) the relationship between the occurrence of impulse control disorders (ICDs) and dyskinesias, and (2) the correlations between specific ICDs and the…Minimizing levodopa titration period for Parkinson’s disease (PD)
Objective: Develop an optimization algorithm that individualizes the pharmacokinetics-pharmacodynamics (PKPD) infusion models of levodopa, to improve the efficacy of dose titration and reduce the number…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Levodopa, placebo and rotigotine change biomarker levels for oxidative stress
Objective: The objective was to investigate the influence of the D1 receptor agonists levodopa and rotigotine compared with placebo on homocysteine and cysteinyl-glycine in plasma…
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 62
- Next Page »